{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:41:25Z","timestamp":1778874085167,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,8,21]],"date-time":"2009-08-21T00:00:00Z","timestamp":1250812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title><jats:p><jats:bold>Aim:\u2003<\/jats:bold> A possible link between the renin\u2013angiotensin\u2013aldosterone system (RAAS) and fibrinolysis has recently been suggested. Systemic infusion of angiotensin II results in an increase in plasminogen activator inhibitor type 1 (PAI\u20101) levels and angiotensin\u2010converting enzyme inhibitors (ACEI) have been shown to decrease PAI\u20101 levels. Moreover, recent data indicated that plasma aldosterone levels were positively correlated with plasma PAI\u20101 levels. This study was designed to compare the effects of an ACEI with an ACEI in combination with an aldosterone antagonist on PAI\u20101 levels in chronic hypertensive patients.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> Patients were randomized into two groups and were treated with either low salt diet plus fosinopril (group 1, <jats:italic>n<\/jats:italic>\u2003=\u200343) or low salt diet plus fosinopril plus spironolactone (group 2, <jats:italic>n<\/jats:italic>\u2003=\u200342). Plasma PAI\u20101, tissue plasminogen activator (tPA) and plasma renin activity (PRA) levels were measured before and after 24\u2003week treatment in both groups.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> The mean basal PRA levels were similar in both groups. After antihypertensive therapy, the mean PRA increased significantly in both groups (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.005). The mean plasma PAI\u20101 levels were reduced in both treatment groups (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.005). However, the reduction in group 2 was more pronounced (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Although after the treatment mean plasma levels of PAI\u20101 significantly reduced in both groups, the reduction of PAI\u20101 levels was more pronounced in group 2.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold> Although the plasma levels of PAI\u20101 significantly reduced after treatment in both groups, the reduction of PAI\u20101 levels was more pronounced in group 2. These data indicated that administration of aldosterone antagonists in combination with ACEI had additional benefit on fibrinolysis in chronic hypertensive patients.<\/jats:p>","DOI":"10.1111\/j.1440-1797.2009.01181.x","type":"journal-article","created":{"date-parts":[[2009,8,21]],"date-time":"2009-08-21T10:19:52Z","timestamp":1250849992000},"page":"211-215","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of combined angiotensin\u2010converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients"],"prefix":"10.1111","volume":"15","author":[{"given":"OZLEM","family":"TIRYAKI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CELALETTIN","family":"USALAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HAKAN","family":"BUYUKHATIPOGLU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,3,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(05)70568-X"},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"157","author":"The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","year":"1997","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"e_1_2_5_4_2","first-page":"9","article-title":"1999 World Health Organization\u2010International Society of Hypertension guidelines for the management of hypertension","volume":"8","author":"Guidleines S","year":"1999","journal-title":"Blood Press."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.87.6.1969"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1172\/JCI117809","article-title":"Angiotensin II regulates the expression of plasminogen activator inhibitor\u20101 in cultured endothelial cells: A potential link between the renin angiotensin system and thrombosis","volume":"95","author":"Vaughen DE","year":"1995","journal-title":"J. Clin. Invest."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00160.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.33.6.1431"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.4.835.835"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011119003788"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2001.tb00064.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.303"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.1.336"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-2712(18)30343-3"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.12.9.1063"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1990.tb00157.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0895-7061(95)00442-4","article-title":"Impaired fibrinolysis and insulin resistance in patients with hypertension","volume":"9","author":"Jeng JR","year":"1996","journal-title":"Am. J. Hypertens."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"e_1_2_5_21_2","first-page":"294","article-title":"Effects of enalapri on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0895-7061(95)00442-4","article-title":"Impaired fibrinolysis and insulin resistance in patients with hypertension","volume":"9","author":"Jeng JR","year":"1996","journal-title":"Am. J. Hypertens."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.2.284"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.16.4.539"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"168S","DOI":"10.1093\/ajh\/4.2.168S","article-title":"Decreased fibrinolytic activity and increased platelet function in hypertension: Possible influence of calcium antagonist","volume":"4","author":"Gleerup G","year":"1991","journal-title":"Am. J. Hypertens."},{"key":"e_1_2_5_26_2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000066348","article-title":"Effect of spironolactone on impaired fibrinolysis of hypertensive patients","volume":"25","author":"Yalcin AU","year":"2002","journal-title":"Kidney Blood Press. Res."},{"key":"e_1_2_5_27_2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1210\/jcem.87.2.7980","article-title":"Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor\u20101 in humans","volume":"87","author":"Swathiparnich P","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.32.6.965"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01982-4"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(82)90390-3"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/16.suppl_N.103"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1797.2009.01181.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1797.2009.01181.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T15:05:50Z","timestamp":1697295950000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1797.2009.01181.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1440-1797.2009.01181.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1797.2009.01181.x","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"2010-03-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}